The global Continuous Glucose Monitoring market continues to exhibit robust growth, with market size valued at USD 4.62 billion in 2023, and projected to reach USD 8.82 billion by 2032, expanding at a Compound Annual Growth Rate (CAGR) of 7.80% during the forecast period.
This strong growth is driven by a surge in diabetes prevalence worldwide, growing awareness of proactive diabetes management, technological advancements in CGM systems, and increasing patient preference for real-time, minimally invasive glucose monitoring solutions.
Key Market Drivers Include:
- Rising incidence of Type 1 and Type 2 diabetes globally
- Increased adoption of wearable and real-time monitoring devices
- Government initiatives promoting early diagnosis and digital health tools
- Integration of CGM systems with insulin pumps and smartphone apps
Get a Sample Report of Continuous Glucose Monitoring Market@ https://www.snsinsider.com/sample-request/3055
Component Insights
Among the major components in CGM systems, the sensor segment dominated the market in 2023, holding 41% of the total revenue share. The growth of this segment is primarily driven by innovations aimed at enhancing sensor accuracy, reliability, and longevity. Subcutaneous sensors, which measure glucose levels in interstitial fluid through a filament thinner than a human hair, form the core of CGM systems. These filaments use glucose oxidase to detect blood glucose levels, triggering a chemical reaction that creates hydrogen peroxide. When platinum-coated layers come into contact with hydrogen peroxide, an electrical signal is produced, providing accurate glucose readings. These chemical layers are designed to endure challenging biological conditions, ensuring consistent performance.
While sensors currently hold the largest share, the transmitter segment is expected to record the highest CAGR of 7.85% during the forecast period. These transmitters, often worn externally and wirelessly linked to subcutaneous sensors, communicate glucose readings to receiving devices or smartphone apps. The wireless transmission typically relies on radio frequencies or Bluetooth technology. These real-time alerts are crucial for proactive diabetes management, especially in cases of hypo- or hyperglycemia. The growing integration of Near Field Communication (NFC) and improved battery life in newer devices further enhances the appeal and usability of modern transmitters.
Connectivity Trends
From a connectivity standpoint, Bluetooth-based CGM systems led the market in 2023, capturing a 60% revenue share. Bluetooth-enabled CGM devices allow seamless data transfer between sensors and handheld devices, giving users immediate access to glucose readings. These chips, manufactured by third-party semiconductor companies like Nordic Semiconductors, Renesas Electronics, and Onsemi, are essential for maintaining consistent and accurate glucose tracking.
Bluetooth chips used in CGM systems generally have a lifespan of 14 days, after which they must be replaced along with the sensors. The 4G network segment, while currently smaller, is anticipated to grow at a CAGR of 7.78%. These systems transfer data to centralized databases, enabling healthcare providers to remotely monitor patients and make informed decisions based on extensive glucose trends. Furthermore, apps such as Glucose Buddy, MySugr, Fooducate, and others enhance patient engagement by offering analytics, meal tracking, and personalized insights. Subscription-based and free apps have seen widespread adoption across age groups and regions, reinforcing the trend toward digital diabetes care.
Need Any Customization Research on Continuous Glucose Monitoring Market, Enquire Now@ https://www.snsinsider.com/enquiry/3055
Regional Insights
North America held the dominant position in the global CGM market in 2023, accounting for a 39% market share. Several factors contributed to this leadership, including a high prevalence of diabetes, robust adoption of CGM technologies, strong healthcare infrastructure, and the presence of leading CGM manufacturers. U.S. government initiatives and reimbursement support have also been instrumental in encouraging the adoption of advanced diabetes management solutions.
Meanwhile, the Asia Pacific region is poised to grow at the highest CAGR of 8.72% through 2032. The region harbors approximately 60% of the world’s diabetic population, as reported by the Asian Diabetes Prevention Initiative. Countries like India and China are witnessing a rapid rise in diabetes cases, which is prompting governments and private players to increase investments in healthcare technology. Improvements in regulatory policies, rising health awareness, and expanding middle-class demographics are expected to further accelerate market growth across this region.
Key Players in the Global CGM Market
A wide array of companies are actively contributing to the competitive landscape of the CGM market. Key market players include:
- Abbott Laboratories – Freestyle Libre 1, 2, and 3 series
- Dexcom – Dexcom G6 and G7 systems
- Medtronic – Enlite sensor, MiniMed 670G and 780G systems
- Tandem Diabetes Care – t:slim X2 insulin pump
- Senseonics Holdings – Eversense XL
- Nipro Corporation – Nipro Cosmos system
- Roche Diagnostics – Accu-Chek Aviva Plus
- Insulet Corporation – Omnipod system
- Medtrum Technologies – MiaoMiao 2 and 3
- Ascensia Diabetes Care – Contour Next Flash and One
- LifeScan – OneTouch Reveal system
- Ypsomed – YpsoPump and YpsoDiab
- ACON Laboratories, ARKRAY, Prodigy Diabetes Care, Terumo Corporation, Sanofi, B. Braun, among others
These companies are investing heavily in R&D to develop next-generation CGM systems that offer better accuracy, improved comfort, and extended wear time.
Recent Developments
In October 2023, Dexcom Inc. launched its Dexcom G7 system in Canada, further strengthening its global footprint. The device received praise for its compact size, fast sensor warm-up, and robust app integration.
In September 2023, Senseonics Holdings Inc. announced successful completion of the ENHANCE Pivotal Clinical Study. The study demonstrated that the Eversense CGM system provided reliable glucose tracking and was effective in supporting long-term diabetes management.
In April 2023, Medtronic Inc. secured U.S. FDA approval for its MiniMed 780G system, which includes the Guardian 4 sensor. This approval marked a significant milestone for Medtronic’s automated insulin delivery systems, emphasizing its leadership in the hybrid closed-loop market.
Buy a Single-User PDF of Continuous Glucose Monitoring Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/3055
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
